Browse > Article
http://dx.doi.org/10.7845/kjm.2013.3048

Probiotics with Antimicrobial Activity against Multidrug Resistant Pseudomonas aeruginosa and Acinetobacter baumannii  

Lee, Do Kyung (College of Pharmacy, Sahmyook University)
Kim, Min Ji (College of Pharmacy, Sahmyook University)
Kang, Joo Yeon (College of Pharmacy, Duksung Women's University)
Park, Jae Eun (College of Pharmacy, Duksung Women's University)
Shin, Hea Soon (College of Pharmacy, Duksung Women's University)
Ha, Nam Joo (College of Pharmacy, Sahmyook University)
Publication Information
Korean Journal of Microbiology / v.49, no.3, 2013 , pp. 245-252 More about this Journal
Abstract
Pseudomonas aeruginosa and Acinetobacter baumannii are significant opportunistic pathogens in hospitals and are resistant to most antibiotics. Multidrug-resistant P. aeruginosa (MDRPA) and A. baumannii (MDRAB) cause severe human nosocomial infections and are more difficult to treat than methicillin-resistant Staphylococcus aureus (MRSA). Bifidobacteria are among of the most beneficial probiotics and have been widely studied for their antimicrobial activities. The present study explored the antimicrobial activity of Bifidobacterium sp. isolated from healthy Koreans against MDRPA and MDRAB. The antimicrobial activity of the isolates against MDRPA and MDRAB, which are resistant to ciprofloxacin, tobramycin, gentamicin, meropenem, and ceftazidime, was determined by modified broth microdilution methods using absorbance. Among all tested bifidobacteria isolates (nine B. adolescentis, three B. longum, and two B. pseudocatenulatum), the culture supernatant of B. pseudocatenulatum SPM1309 showed a strong growth inhibitory effect against MDRPA and MDRAB. No change in the turbidity of the mixture was observed during incubation, and its inhibitory effect occurred through bacteriostastic action. Moreover, the antibacterial activity was observed in the fraction with molecular weights <10 kDa of bifidobacteria culture supernatant, and the active fraction was heat-stable because it maintained its activity when heated at $70^{\circ}C$ for 10 min. The results suggest that this Bifidobacterium strain could have potential applications for alternative therapy in MDRPA and MDRAB infections.
Keywords
Bifidobacterium; antimicrobial activity; multidrug-resistant Acinetobacter baumannii; multidrug-resistant Pseudomonas aeruginosa;
Citations & Related Records
연도 인용수 순위
  • Reference
1 O'Riordan, K. and Fitzgerald, G.F. 1998. Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature. J. Appl. Microbiol. 85, 103-114.   DOI   ScienceOn
2 Parvez, S., Malik, K.A., Ah Kang, S., and Kim, H.Y. 2006. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 100, 1171-1185.   DOI   ScienceOn
3 Rodriguez, E., Arques, J.L., Rodriguez, R., Peiroten, A., Landete, J.M., and Medina, M. 2012. Antimicrobial properties of probiotic strains isolated from breast-fed infants. J. Funct. Foods 4, 542-551.   DOI   ScienceOn
4 Servin, A.L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. 28, 405–440.   DOI   ScienceOn
5 Shah, P.M. 2005. The need for new therapeutic agents: what is the pipeline? Clin. Microbiol. Infect. 11, 36-42.
6 Tissier, H. 1990. Ph. D. Thesis, University of Paris, Paris, France.
7 Trottier, V., Segura, P.G., Namias, N., King, D., Pizano, L.R., and Schulman, C.I. 2007. Outcomes of Acinetobacter baumannii infection in critically I11 burned patients. J. Burn. Care Res. 28, 248-254.   DOI
8 Yildirim, Z. and Johnson, M.G. 1998. Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454. J. Food Prot. 61, 47-51.   DOI
9 Yildirim, Z., Winters, D.K., and Johnson, M.G. 1999. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB 1454. J. Appl. Microbiol. 86, 45-54.   DOI   ScienceOn
10 Ibrahim, S.A. and Salameh, M.M. 2001. Simple and rapid method for screening antimicrobial activities of Bifidobacterium species of human isolates. J. Rapid Methods Autom. Microbiol. 9, 52-63.
11 Kondepudi, K.K., Ambalam, P., Nilsson, I., Wadstrom, T., and Ljungh, A. 2012. Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile. Anaerobe 18, 489–497.   DOI   ScienceOn
12 Marteau, P. and Shanahan, F. 2003. Basic aspects and pharmacology of probiotics: An overview of pharmacokinetics mechanisms of action and side-effects. Best Pract. Res. Clin. Gastroenterol. 17, 725-740.   DOI   ScienceOn
13 Kuo, L.C., Teng, L.J., Yu, C.J., Ho, S.W., and Hsueh, P.R. 2004. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J. Clin. Microbiol. 42, 1759-1763.   DOI   ScienceOn
14 Makras, L. and De Vuyst, L. 2006. The in vitro inhibition of Gram-negative pathogenic bacteria by bifidobacteria is caused by the production of organic acids. Int. Dairy J. 16, 1049-1057.   DOI   ScienceOn
15 Marshall, J.C., Christou, N.V., and Meakins, J.L. 1993. The gastrointestinal tract. The "undrained abscess" of multiple organ failure. Ann. Surg. 218, 111-119.   DOI
16 Matsumoto, T., Ishikawa, H., Tateda, K., Yaeshima, T., Ishibashi, N., and Yamaguchi, K. 2007. Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. J. Appl. Microbiol. 104, 672-680.
17 Navon-Venezia, S., Ben-Ami, R., and Carmeli, Y. 2005. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr. Opin. Infect. Dis. 18, 306-313.   DOI   ScienceOn
18 Ohara, T. and Itoh, K. 2003. Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. Int. Med. 42, 1072-1076.   DOI
19 Gaynes, R. and Edwards, J.R. 2005. National nosocomial infections surveillance system. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41, 848-854.   DOI   ScienceOn
20 Gibson, G.R. and Wang, X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J. Appl. Bacteriol. 77, 412-420.   DOI   ScienceOn
21 Anand, S.K., Srinivasan, R.A., and Rao, L.K. 1985. Antimicrobial activity associated with Bifidobacterium bifidum-II. Cult. Dairy Products J. 20, 21-23.
22 Gill, H.S. and Guarner, F. 2004. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80, 516-526.   DOI   ScienceOn
23 Gomes, A.M.P. and Malcata, F.X. 1999. Bifidobacterium spp. and Lactobacillus acidophilus: Biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trends Food Sci. Technol. 10, 139-157.   DOI   ScienceOn
24 Ahn, J.B. 2005. Isolation and characterization of Bifidobacterium producing exopolysaccharide. Food Eng. Prog. 9, 291-296.
25 Guarner, F. and Malagelada, J.R. 2003. Gut flora in health and disease. Lancet 361, 512–519.   DOI   ScienceOn
26 Gupta, V. and Garg, R. 2009. Probiotics. Indian J. Med. Microbiol. 27, 202-209.   DOI   ScienceOn
27 Hammes, W.P. and Tichaczek, P.S. 1994. The potential of lactic acid bacteria for the production of safe and wholesome food. Z. Lebensm. Unters. Forsch. 198, 193-201.   DOI   ScienceOn
28 Hentges, D.J., Stein, A.J., Casey, S.W., and Que, J.U. 1985. Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance. Infect. Immun. 47, 118-122.
29 Iannitti, T. and Palmieri, B. 2010. Therapeutical use of probiotic formulations in clinical practice. Clin. Nutr. 29, 701-725.   DOI   ScienceOn
30 Ballongue, J. 1998. Bifidobacteria and probiotic action. pp. 519-587. In Salminen, S. and Von Wright, A. (eds.), Lactic Acid Bacteria: Microbiology and Functional Aspects. Marcel Dekker, New York, USA.
31 Clinical and Laboratory Standards Institute (CLSI). 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard, 9th ed. CLSI document M07-A79, CLSI, Wayne, PA, USA.
32 Bassetti, M., Righi, E., Esposito, S., Petrosillo, N., and Nicolini, L. 2008. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 3, 649–660.   DOI   ScienceOn
33 Cheikhyoussef, A., Pogori, N., Chen, W., and Zhang, H. 2008. Antimicrobial proteinaceous compounds obtained from bifidobacteria: From production to their application. Int. J. Food Microbiol. 125, 215-222.   DOI   ScienceOn
34 Chevalier, P., Roy, D., and Ward, D. 1990. Detection of Bifidobacterium species by enzymatic methods. J. Appl. Bacteriol. 68, 619-624.   DOI
35 De Vuyst, L., Avonts, L., and Makras, L. 2004. Probiotics, prebiotics and gut health. pp. 416-482. In Remacle, C. and Reusens, B. (eds.), Functional Foods, Ageing and Degenerative Disease. Woodhead Publishing, Cambridge, UK.
36 Deplano, A., Denis, O., Poirel, L., Hocquet, D., nonhoff, C., Byl, B., Nordmann, P., Vincent, J.L., and Struelens, M.J. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43, 1198-1204.   DOI   ScienceOn
37 Falagas, M.E., Bliziotis, I.A., Kasiakou, S., Samonis, G., Athanassopoulou, P., and Michalopoulos, A. 2005. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis. 5, 24 doi:10.1186/1471-2334-5-24.   DOI   ScienceOn
38 Falagas, M.E. and Kopterides, P. 2006. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J. Hosp. Infect. 64, 7-15.   DOI   ScienceOn
39 Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66, 365-378.   DOI